Evolving strategies for patients with MRD+ B-ALL. Patients with CD19+ and/or CD22+ B-ALL in CR and MRD+ (CR MRD+) can be offered Blina (lower curve7) or InO (upper curve1), resulting in MRD negativity in 70% of the patients and RFS of 50%. Whether allo-SCT may be offered as intensification in responding patients remains a matter of debate. CI, confidence interval; HSCT, hematopoietic stem cell transplantation.
